Antisoma announces promising preliminary phase II data for AS1404 in lung cancer

18-Oct-2005 - Antisoma announced preliminary findings from an ongoing phase II trial of AS1404 in lung cancer. With initial data available from 47 of the 71 patients enrolled, those receiving AS1404 in addition to chemotherapy showed a higher frequency of tumour responses (43.5% vs 33.3%) and a lower frequency ...

Development of blood diagnostics for the early detection of cancers

bioMérieux and ExonHit Therapeutics Extend their Strategic Collaboration

14-Oct-2005 - bioMérieux and ExonHit announced that they signed an agreement to extend their collaboration for six years for the discovery and development of new blood diagnostics in the area of early cancer detection. These diagnostic tests are completely novel because they should enable the detection of ...

Cancer Target Collaboration Agreement Signed Between MedImmune and Georgetown University

28-Sep-2005 - MedImmune, Inc. announced that it has entered into a licensing and collaboration agreement with Georgetown University for the development of monoclonal antibodies (MAbs) targeting anaplastic lymphoma kinase (ALK), a member of the insulin receptor family of tyrosine kinases. ALK is believed to ...

First patient treated in extended phase I trial of Antisoma's AS1411

07-Sep-2005 - Cancer drug developer Antisoma announced that it has reopened a US phase I trial of its aptamer drug AS1411 following the presentation of promising data at this year's American Society of Clinical Oncology meeting. The study is now enrolling patients with renal and non-small cell lung cancers. ...

Lorus identifies novel class of lead drug candidates from small molecule anticancer program

26-Aug-2005 - Lorus Therapeutics Inc. announced the continued success in the development of its small molecule anticancer program with the selection of a sub-class of lead molecules from the Company's small molecule program. Two molecules from this sub-class, ML-133 and LT-253, have been chosen as lead ...

UCB and Imclone Systems enter into worldwide partnership for CDP-791 therapy targeting the development of tumor vasculature

18-Aug-2005 - UCB and ImClone Systems Incorporated announced that they have entered into a worldwide strategic partnership for the development and commercialization of CDP-791, a novel, investigational antibody targeting the vascular endothelial growth factor receptor-2 (VEGFR-2) that is currently being ...

Protox signs exclusive Lung Cancer licence agreement and initiates Lung Cancer study

11-Aug-2005 - Protox Therapeutics Inc. announced that it has signed an exclusive licence agreement with the National Research Council Institute for Biological Sciences (NRC-IBS) and the University of Victoria (UVic) Innovation and Development Corporation (IDC). The licence grants Protox exclusive worldwide ...

Cancer Research Yields Promising Results

Closing Gap between Research Advances and Clinical Practice Crucial to Development of European

04-Aug-2005 - Every year, nearly one in four Europeans - a total of almost one million people - dies from cancer, giving Europe the dubious distinction of having amongst the highest cancer-related mortality rates in the world. Even as cancer remains a difficult disease to diagnose, often resulting in either ...

Cell Genesys Reports Clinical Data From GVAX® Vaccine For Lung Cancer Program

06-Jul-2005 - Cell Genesys, Inc. reported data from a Phase 2 clinical trial of GVAX® vaccine for lung cancer, a patient-specific vaccine for patients with advanced-stage, non small-cell lung cancer (NSCLC). The trial, which is the second Phase 2 trial in this indication, enrolled 101 patients who were ...

Protox receives funding from NRC to develop lung cancer drug

09-Jun-2005 - Protox Therapeutics Inc. announced that it has received a financial contribution of up to $340,000 from the National Research Council ('NRC') Industrial Research Assistance Program ('IRAP'). The NRC has committed this money to the Company to support its development of Lung-H1, a therapeutic toxin ...